42 Chapter 2 REFERENCES 1. Lammertsma AA (2017) Forward to the past: the case for quantitative PET imaging. J Nucl Med 58:1019–1024 2. Ossenkoppele R, Prins ND and van Berckel BN. Amyloid imaging in clinical trials. Alzheimer’s research & therapy 2013; 5: 36. 2013/08/21. https://doi.org/10.1186/alzrt195 3. Joseph-Mathurin N, Su Y, Blazey TM, Jasielec M, Vlassenko A, Friedrichsen K, Gordon BA, Hornbeck RC, Cash L, Ances BM, Veale T, Cash DM, Brickman AM, Buckles V, Cairns NJ, Cruchaga C, Goate A, Jack CR Jr, Karch C, Klunk W, Koeppe RA, Marcus DS, Mayeux R, McDade E, Noble JM, Ringman J, Saykin AJ, Thompson PM, Xiong C, Morris JC, Bateman RJ, Benzinger TLS, Dominantly Inherited Alzheimer Network (2018)Utility of perfusion PETmeasures to assess neuronal injury in Alzheimer’s disease. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10:669–677 4. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging- Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 2012; 8: 1–13. 2012/01/24. https:// doi.org/10.1016/j.jalz.2011.10.007 5. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Tredici KD, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362–381 6. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42:631–631 7. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. Journal of Alzheimer’s disease : JAD 2013; 34: 457–468. 2012/12/14. https://doi.org/10.3233/jad-122059 8. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Annals of neurology 2016; 79: 110–119. 2015/10/28. https://doi.org/10.1002/ana.24546 9. Xia CF, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 2013; 9: 666–676. 2013/02/16. https://doi.org/10.1016/j.jalz.2012.11.008 10. Yaqub M, Tolboom N, Boellaard R, et al. Simplified parametric methods for [11C]PIB studies. NeuroImage 2008; 42: 76–86. 2008/06/11. https://doi.org/10.1016/j.neuroimage.2008.04.251
RkJQdWJsaXNoZXIy MjY0ODMw